150
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial

, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 3325-3335 | Published online: 29 Sep 2020

References

  • Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50(2):303–316. doi:10.4143/crt.2018.143
  • Biganzoli E, Desmedt C, Fornili M, et al. Recurrence dynamics of breast cancer according to baseline body mass index. Eur J Cancer. 2017;87:10–20. doi:10.1016/j.ejca.2017.10.007
  • Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–397.
  • Kroes M, Osei-Assibey G, Baker-Searle R, Huang J. Impact of weight change on quality of life in adults with overweight/obesity in the United States: a systematic review. Curr Med Res Opin. 2016;32(3):485–508. doi:10.1185/03007995.2015.1128403
  • Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118(11):1786–1807. doi:10.1161/CIRCRESAHA.115.306885
  • Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–635. doi:10.1200/JCO.2015.64.3809
  • Rock CL, Flatt SW, Byers TE, et al. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: a behavioral weight loss intervention in overweight or obese breast cancer survivors. J Clin Oncol. 2015;33(28):3169–3176. doi:10.1200/JCO.2015.61.1095
  • Harrigan M, Cartmel B, Loftfield E, et al. Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: the Lifestyle, Exercise, and Nutrition (LEAN) study. J Clin Oncol. 2016;34(7):669–676. doi:10.1200/JCO.2015.61.6375
  • Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. J Am Coll Cardiol. 2014;63(25Pt B):2985–3023. doi:10.1016/j.jacc.2013.11.004
  • Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med. 2013;368(14):1279–1290. doi:10.1056/NEJMoa1200303
  • Becerra-Tomás N, Blanco Mejía S, Viguiliouk E, et al. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials. Crit Rev Food Sci Nutr. 2020;60(7):1207–1227. doi:10.1080/10408398.2019.1565281
  • Schwingshackl L, Schwedhelm C, Galbete C, Hoffmann G. Adherence to mediterranean diet and risk of cancer: an updated systematic review and meta-analysis. Nutrients. 2017;9(10):10. doi:10.3390/nu9101063
  • Toledo E, Salas-Salvadó J, Donat-Vargas C, et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED trial: a randomized clinical trial. JAMA Intern Med. 2015;175(11):1752–1760. doi:10.1001/jamainternmed.2015.4838
  • Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2010;376(9741):595–605. doi:10.1016/S0140-6736(10)60888-4
  • Zagon IS, Donahue R, McLaughlin PJ. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood). 2013;238(5):579–587. doi:10.1177/1535370213488483
  • Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018;61:178–184. doi:10.1016/j.intimp.2018.05.020
  • Nuñez GR, Pinczowski H, Zanellato R, et al. Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot Phase II trial. J Pain Symptom Manage. 2013;45(6):969–979. doi:10.1016/j.jpainsymman.2012.06.011
  • Mathias C, Cardeal Mendes CM, Pondé de Sena E, et al. An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol. 2006;17(12):1792–1796. doi:10.1093/annonc/mdl304
  • WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3
  • Schröder H, Fitó M, Estruch R, et al. A short screener is valid for assessing mediterranean diet adherence among older Spanish men and women. J Nutr. 2011;141(6):1140–1145. doi:10.3945/jn.110.135566
  • Simapivapan P, Boltong A, Hodge A. To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review. Cancer Treat Rev. 2016;50:155–167. doi:10.1016/j.ctrv.2016.09.010
  • Cho JW, Kweon MR, Park YM, et al. A survey of diabetic educators and patients for the revision of korean food exchange lists. Diabetes Metab J. 2011;35(2):173–181. doi:10.4093/dmj.2011.35.2.173
  • Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. doi:10.1093/clinchem/18.6.499
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi:10.1007/BF00280883
  • Yun YH, Park YS, Lee ES, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004;13(4):863–868. doi:10.1023/B:QURE.0000021692.81214.70
  • Lee YJ, Moon KH, Choi JH, Cho MJ, Shin SH, Heo Y. Validation of the Korean translation of obesity-related problems scale assessing the quality of life in obese Korean. J Korean Surg Soc. 2013;84(3):140–153. doi:10.4174/jkss.2013.84.3.140
  • Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1(1):79. doi:10.1186/1477-7525-1-79
  • Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943. doi:10.1002/oby.20309
  • Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120. doi:10.1038/oby.2010.147
  • Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, mediterranean, or low-fat diet. N Engl J Med. 2008;359(3):229–241. doi:10.1056/NEJMoa0708681
  • Bajerska J, Chmurzynska A, Muzsik A, et al. Weight loss and metabolic health effects from energy-restricted mediterranean and Central-European diets in postmenopausal women: a randomized controlled trial. Sci Rep. 2018;8(1):11170. doi:10.1038/s41598-018-29495-3
  • Estruch R, Martínez-González MA, Corella D, et al. Effects of a mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145(1):1–11. doi:10.7326/0003-4819-145-1-200607040-00004
  • Due A, Larsen TM, Hermansen K, et al. Comparison of the effects on insulin resistance and glucose tolerance of 6-mo high-monounsaturated-fat, low-fat, and control diets. Am J Clin Nutr. 2008;87(4):855–862. doi:10.1093/ajcn/87.4.855
  • Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011;46(3):209–228. doi:10.1007/s11745-010-3524-y
  • Kwan HY, Chao X, Su T, et al. The anticancer and antiobesity effects of mediterranean diet. Crit Rev Food Sci Nutr. 2017;57(1):82–94. doi:10.1080/10408398.2013.852510
  • Menendez JA, Papadimitropoulou A, Vellon L, Lupu R. A genomic explanation connecting “mediterranean diet”, olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory “PEA3 transcription factor-PEA3 DNA binding site” complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. Eur J Cancer. 2006;42(15):2425–2432. doi:10.1016/j.ejca.2005.10.016
  • Akl MR, Ayoub NM, Mohyeldin MM, et al. Olive phenolics as c-Met inhibitors: (-)-oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS One. 2014;9(5):e97622. doi:10.1371/journal.pone.0097622